Guide

Is compounded GLP-1 still legal?

Yes, but far more narrowly than in 2024 — and the FDA moved again this year. What changed, and what to ask.

Illustration of an open book with a path drawn across it

Updated 2026-09-18 · every price checked by hand

Cheap GLP-1 medication exists because of compounding. So it matters a great deal whether compounding is still allowed, and the answer has changed three times in two years.

Compounded GLP-1s are no longer the freely marketed product they were in 2024. They remain legal in a narrower form, and the rules changed again in 2026.

The timeline

WhenWhat happened
December 2024FDA declared the tirzepatide shortage resolved.
February 2025FDA declared the semaglutide shortage resolved, ending the shortage-based pathway that allowed large-scale compounding.
16 September 2025FDA issued more than 55 warning letters to online sellers of compounded GLP-1 medications.
1 April 2026FDA reminded compounders that specific conditions must be met for compounded drugs to qualify for exemptions under sections 503A and 503B.
30 April 2026FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, saying there is no clinical need for compounded versions.
30 July 2026Comment period on that proposal closed after an extension.
December 2025FDA approved the first oral GLP-1 for weight management, the Wegovy pill, which launched in the US on 5 January 2026 from $149/month.
1 April 2026FDA approved Foundayo (orforglipron), the first oral small-molecule GLP-1 for weight management, with self-pay from $149/month.
6 May 2026CMS announced the Medicare GLP-1 Bridge, giving eligible Part D beneficiaries certain GLP-1s for $50 a month from 1 July 2026 through 31 December 2027.

What it means if you are buying now

  • A 503A pharmacy may still compound a GLP-1 for an individual patient when there is a documented, patient-specific clinical reason — for example a required dose or formulation that the approved product does not provide.
  • Routinely marketed, off-the-shelf compounded GLP-1 sold like a consumer product is not permitted under that framework.
  • If the 503B Bulks List proposal is finalised, outsourcing facilities would lose the pathway they have been using to produce these drugs in volume.
  • Compounded versions are not FDA-approved. The agency does not review them for safety, effectiveness or manufacturing quality the way it reviews Zepbound or Wegovy.
  • The price argument for compounding is much weaker than it was. Two FDA-approved oral GLP-1s now start at $149 a month, and eligible Medicare beneficiaries can access certain GLP-1s for $50 a month from July 2026 — both below what many compounded programmes charge.

The part that matters most. Compounded versions are not FDA-approved. The agency has not reviewed them for safety, effectiveness or manufacturing quality the way it reviewed Zepbound and Wegovy. That is not the same as saying they are unsafe — but it is a genuine difference, and a price comparison that ignores it is not telling you the whole story.

Five questions worth asking any provider

  1. Which pharmacy fills this, and is it a 503A or 503B facility?
  2. What is the patient-specific clinical reason for compounding in my case?
  3. What happens to my prescription — and my prepaid months — if the 503B Bulks List proposal is finalised?
  4. Can you move me to an FDA-approved product without restarting, and at what price?
  5. Is the figure I have been quoted the ongoing price or an introductory one?

That third question matters most if you are considering an annual plan. We cover the trade-off in annual versus monthly.

If you would rather avoid the question

Through LillyDirect self-pay, single-dose Zepbound vials at 5 mg, 7.5 mg and 10 mg have been listed at $499/month, with lower starting doses nearer $299-$349. Through NovoCare, Wegovy has been offered at $199/month for the first two fills through 31 December 2026, then $349/month for 0.25-2.4 mg doses. The oral form is listed between $149 and $299/month by dose. Ro works exclusively with approved products, and Mochi and LifeMD will chase insurance coverage for you.

Read next

How to cut your GLP-1 billSeven checks that routinely save $1,000 or more a year on exactly the same prescription.The cheapest tirzepatide programmes20 programmes priced over a full year with every fee counted. Coreage Rx is cheapest at $2,388.Annual or monthly?Annual plans carry the best rates and the worst exit terms. How to work out whether the discount is worth it.Tirzepatide vs semaglutideOne works better. The other is cheaper. Here is the actual size of both gaps.Best value GLP-1 programmesCheapest is one question; best value is another. Where each programme actually earns what it charges.

Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure